Evidence map›Paper›PMID 41757208›Full record

ArticlemedRxiv : the preprint server for health sciences2026

Parsing Neurometabolic Signatures of Multiple Sclerosis with MRSI and cPCA.

Narendiran Raghu, Mohammad Abbasi, Zeinab Tashi, Cristian Zamora, Shundene Key, Catherine D Chong, Simona Niklova, Yuxiang Zhou, Edward Ofori, Benjamin B Bartelle

Abstract readPreprint
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Narendiran RaghuArizona State University, School of Biological and Health Systems Engineering. Tempe Arizona, USA.
Mohammad AbbasiArizona State University, School of Biological and Health Systems Engineering. Tempe Arizona, USA.
Zeinab TashiArizona State University, School of Biological and Health Systems Engineering. Tempe Arizona, USA.
Cristian ZamoraArizona State University, School of Biological and Health Systems Engineering. Tempe Arizona, USA.
Shundene KeyArizona State University, School of Biological and Health Systems Engineering. Tempe Arizona, USA.
Catherine D ChongMayo Clinic, Department of Neurology, Phoenix, Arizona, USA.
Simona NiklovaFlorida State University, Dept of Psychology, Neurology and Neuroimaging Research, Tallahassee, FL.
Yuxiang ZhouMayo Clinic, Department of Neurology, Phoenix, Arizona, USA.
Edward OforiArizona State University, College of Health Solutions. Phoenix Arizona, USA.
Benjamin B BartelleArizona State University, School of Biological and Health Systems Engineering. Tempe Arizona, USA.ORCID 0000-0002-5044-369X

Funding

Bioengineering Tools to Resolve and Manipulate Neuroimmune SignalingDP2MH136493 · NIMH · ARIZONA STATE UNIVERSITY-TEMPE CAMPUS · PI Benjamin B Bartelle · 2023 to 2026
$2.3M
NIMH NIH HHS DP2 MH136493
6 · The paper itself

Abstract

Magnetic Resonance Spectroscopy Imaging (MRSI) offers spatially-resolved, neurometabolic information, acquired non-invasively at whole-brain scales from human subjects. Analysis of MRSI however, is extremely challenging. The metabolic information is highly convolved, and sparsely distributed across millions of spatial-spectral datapoints, allowing for little direct human interpretation. Conversely, the overall low signal-to-noise with high-intensity artifacts can confound unsupervised machine learning approaches. These technical barriers have left much of the potential of MRSI unrealized. We acquired MRSI data from 4 human subjects with a diagnosis of multiple sclerosis (MS), incorporating experimental design into an informed machine learning approach. MRSI acquisitions were registered to anatomical MRI to label 105k spectra from brain tissue and 162 spectra from white matter hyperintensities (WMHs), an imaging biomarker associated with MS lesions. Spectral labels were then used in contrastive principal component analysis (cPCA) to filter artifacts and background features in the MRSI data from lesion salient features and clustered into statistically significant states based on features that could be interpreted from the original data. Our approach renders MRSI data into testable representations of neurometabolism, enabling the method for fundamental and clinical research.

Identifiers

PMID41757208
PMCPMC12934854

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.